Loading company
Latest annual · FY2025
Millions- Total revenues
- 70
- Operating income
- 13
- Net income
- 22
- Free cash flow
- (62)
Latest quarter · Q3 FY2026
Millions- Total revenues
- 0
- Operating income
- (12)
- Net income
- (10)
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- n/m
- Revenue, 5 yearsFY2020 to FY2025
- n/m
- Net income, 5 yearsFY2020 to FY2025
- n/m
Black Diamond Therapeutics, Inc. (BDTX) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $70 million | $0 | 10-K 2026-03-16 · proof | |
| Operating income | $12.5 million | -$78.8 million | 10-K 2026-03-16 · proof | |
| Net income | $22.4 million | -$69.7 million | 10-K 2026-03-16 · proof | |
| Cash from operating activities | $29.6 million | -$62.3 million | 10-K 2026-03-16 · proof | |
| Total assets | $143 million | $122.6 million | +16.6% | 10-K 2026-03-16 · proof |
| Total liabilities | $30.8 million | $39.4 million | -21.7% | 10-K 2026-03-16 · proof |
| Cash and cash equivalents | $21 million | $36.4 million | -42.4% | 10-K 2026-03-16 · proof |
- What was Black Diamond Therapeutics, Inc. (BDTX)'s revenue in fiscal 2025?
- Black Diamond Therapeutics, Inc. (BDTX) reported revenue of $70 million for fiscal 2025 (the year ended Dec 31, 2025), against $0 the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Black Diamond Therapeutics, Inc. (BDTX)'s operating income in fiscal 2025?
- Black Diamond Therapeutics, Inc. (BDTX) reported operating income of $12.5 million for fiscal 2025 (the year ended Dec 31, 2025), against -$78.8 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Black Diamond Therapeutics, Inc. (BDTX)'s net income in fiscal 2025?
- Black Diamond Therapeutics, Inc. (BDTX) reported net income of $22.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$69.7 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What was Black Diamond Therapeutics, Inc. (BDTX)'s cash from operating activities in fiscal 2025?
- Black Diamond Therapeutics, Inc. (BDTX) reported cash from operating activities of $29.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$62.3 million the year before. Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Black Diamond Therapeutics, Inc. (BDTX)'s total assets?
- As of Dec 31, 2025, Black Diamond Therapeutics, Inc. (BDTX) reported total assets of $143 million, against $122.6 million a year earlier (+16.6%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Black Diamond Therapeutics, Inc. (BDTX)'s total liabilities?
- As of Dec 31, 2025, Black Diamond Therapeutics, Inc. (BDTX) reported total liabilities of $30.8 million, against $39.4 million a year earlier (-21.7%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
- What are Black Diamond Therapeutics, Inc. (BDTX)'s cash and cash equivalents?
- As of Dec 31, 2025, Black Diamond Therapeutics, Inc. (BDTX) reported cash and cash equivalents of $21 million, against $36.4 million a year earlier (-42.4%). Source: the 10-K filed with the SEC on Mar 16, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BDTX&period_type=annual&limit=5"Information only, not investment advice.